The cellular and molecular components required for the formation of premetastatic niche (PMN) to promote lung metastasis need to be further investigated. Lung epithelial cells have been reported to exhibit immunomodulatory roles in lung homeostasis and also to mediate immunosuppressive PMN formation in lung metastasis. Here, by single-cell sequencing, we identified a tumor-polarized subpopulation of alveolar type 2 (AT2) epithelial cells with increased expression of glutathione peroxidase 3 (GPX3) and high production of interleukin (IL)-10 in the PMN. IL-10-producing GPX3 + AT2 cells inhibited CD4 + T cell proliferation but enhanced regulatory T cell generation. Mechanistically, tumor exosome-inducing GPX3 expression is required for GPX3 + AT2 cells to preferentially produce IL-10 by stabilizing hypoxia-inducible factor 1 (HIF-1α) and promoting HIF-1α-induced IL-10 production. Accordingly, conditional knockout of GPX3 in AT2 cells suppressed lung metastasis in spontaneous metastatic models. Together, our findings reveal a role of tumor-polarized GPX3 + AT2 cells in promoting lung PMN formation, adding insights into immune evasion in lung metastasis and providing potential targets for the intervention of tumor metastasis.
Depression is a highly heterogeneous psychiatric disorder with its pathogenesis increasingly linked to dysregulated neuroinflammation. Microglia, as the resident immune cells of the central nervous system (CNS), play a pivotal role in the initiation and progression of the neuroinflammation and the pathophysiology of depression. These cells exhibit a dual role in pro- and anti-inflammatory processes, dynamically regulating immune responses through immunometabolic reprogramming in response to environmental cues. This review elaborates how metabolic remodeling in microglia, particularly within glucose, lipid, and amino acid pathways, drives their polarization toward a pro-inflammatory phenotype. This shift promotes depression pathogenesis via the release of inflammatory factors, disruption of synaptic plasticity, and mediation of neurotoxicity. We further discuss the impact of existing antidepressants on cellular metabolism and highlight the promise and challenges of targeting specific microglial metabolic pathways as a novel therapeutic strategy. This synthesis provides new insights into the immunometabolic mechanisms of depression and outlines directions for developing targeted treatments.
Background: Pancreatic ductal adenocarcinoma (PDAC) is an exceptionally lethal malignancy, with high percents of patients presenting with liver metastases (LM). However, the mechanisms driving liver metastases remain critical bottlenecks requiring urgent exploration. Objective: To identify the key cellular subsets driving PDAC liver metastases, elucidate their interactions with the metastatic microenvironment, and define the underlying mechanisms of liver colonization. Materials and Methods: Integrated single‐cell transcriptomic analysis was performed using scRNA‐seq data of PT and LM. The expression of signature genes within the identified cell subset was validated using clinical samples from PDAC PT and LM patients. Furthermore, ligand‐receptor network analysis was conducted between the specific tumor cell subset and key immune cells. Results: We identified a novel liver‐enriched metastatic subset (LEMS), a terminally differentiated malignant cell subpopulation characterized by metabolic reprogramming and hyperactivation of immunosuppressive pathways. We further validated the LEMS signature genes, oxidized low‐density lipoprotein receptor 1 (OLR1) and solute carrier family 7 member 7 (SLC7A7), as potential diagnostic biomarkers for liver metastases. Importantly, we found that SPP1 + macrophages interacted with LEMS via ligand‐receptor networks, thereby driving invasion and immune evasion. Discussion: We revealed the highly malignant features of LEMS and crosstalk between LEMS and SPP1 + macrophages in liver metastases. However, it is necessary to expand clinical cohorts and in vivo models to comprehensively elucidate the specific mechanistic interactions between LEMS and macrophages. Conclusion: We delineated LEMS as an enriched subset in LM and proposed targeting of LEMS‐SPP1 + macrophage interactions as a therapeutic strategy to disrupt metastatic progression.